• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

    26.10 +0.36 (+1.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 815,071
    Open 26.24
    Bid (Size) 10.45 (200)
    Ask (Size) 26.10 (100)
    Prev. Close 25.74
    Today's Range 25.80 - 26.87
    52wk Range 9.570 - 30.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Top movers in Friday's after hours session ↗
    Via Chartmill

    Performance

    YTD
    +59.3%
    +59.3%
    1 Month
    -10.7%
    -10.7%
    3 Month
    +14.9%
    +14.9%
    6 Month
    +55.7%
    +55.7%
    1 Year
    +134.7%
    +134.7%

    More News

    Read More
    News headline image
    Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗
    Via Chartmill
    News headline image
    Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara (BCAX) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
    Via MarketBeat
    News headline image
    Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗
    Via MarketBeat
    News headline image
    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara (BCAX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Bicara Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Bicara Therapeutics Inc. - Common Stock publicly traded?
    Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
    Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
    The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
    What is the current price of Bicara Therapeutics Inc. - Common Stock?
    The current price of Bicara Therapeutics Inc. - Common Stock is 26.10
    When was Bicara Therapeutics Inc. - Common Stock last traded?
    The last trade of Bicara Therapeutics Inc. - Common Stock was at 08/04/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.